{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:08:14Z","timestamp":1767006494142},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Major R&D Program of China","award":["2016YFC1201000"],"award-info":[{"award-number":["2016YFC1201000"]}]},{"name":"Institut Pasteur of Shanghai, Chinese Academy of Sciences","award":["KLMVI-Ebola-2014002"],"award-info":[{"award-number":["KLMVI-Ebola-2014002"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.antiviral.2017.07.009","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T02:46:22Z","timestamp":1500432382000},"page":"54-59","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice"],"prefix":"10.1016","volume":"145","author":[{"given":"Tan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.07.009_bib1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.07.009_bib2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.07.009_bib3","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.07.009_bib4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.07.009_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection","volume":"477","author":"Cote","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.07.009_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4155\/pbp.13.18","article-title":"The use of Drosophila S2 cells in R&D and bioprocessing","volume":"1","author":"de Jongh","year":"2013","journal-title":"Pharm. Bioprocess."},{"key":"10.1016\/j.antiviral.2017.07.009_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A\u00a0monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.07.009_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/527453a","article-title":"Ebola: hidden reservoirs","volume":"527","author":"Heeney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.07.009_bib9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.07.009_bib10","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1056\/NEJMp1412166","article-title":"Ebola vaccine\u2013an urgent international priority","volume":"371","author":"Kanapathipillai","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.07.009_bib11","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1073\/pnas.1019030108","article-title":"T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus","volume":"108","author":"Kondratowicz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.antiviral.2017.07.009_bib12","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1086\/514294","article-title":"Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections","volume":"179","author":"Kudoyarova-Zubavichene","year":"1999","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.07.009_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.07.009_bib14","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1128\/JVI.01239-16","article-title":"An Ebola virus-like particle-based reporter system enables evaluation of antiviral drugs in\u00a0vivo under non-biosafety level 4 conditions","volume":"90","author":"Li","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.07.009_bib15","doi-asserted-by":"crossref","first-page":"10486","DOI":"10.1128\/JVI.01462-16","article-title":"Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice","volume":"90","author":"Li","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.07.009_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/14760584.2016.1187566","article-title":"Ebola virus disease candidate vaccines under evaluation in clinical trials","volume":"15","author":"Martins","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2017.07.009_bib17","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.07.009_bib18","doi-asserted-by":"crossref","first-page":"e36192","DOI":"10.1371\/journal.pone.0036192","article-title":"Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever","volume":"7","author":"Marzi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2017.07.009_bib19","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2017.07.009_bib20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/14760584.2016.1178068","article-title":"Ebola virus vaccines - reality or fiction?","volume":"15","author":"Mire","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2017.07.009_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.07.009_bib22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virusres.2015.10.021","article-title":"Recent advances in the development of vaccines for Ebola virus disease","volume":"211","author":"Ohimain","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2017.07.009_bib23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1473-3099(15)00416-8","article-title":"The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats","volume":"16","author":"Osterholm","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.07.009_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.07.009_bib25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2017.07.009_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2017.07.009_bib27","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8(+) cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2017.07.009_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.07.009_bib29","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.07.009_bib30","doi-asserted-by":"crossref","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2017.07.009_bib31","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.72.4.3155-3160.1998","article-title":"Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines","volume":"72","author":"Wool-Lewis","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.07.009_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.micinf.2014.12.004","article-title":"Development of vaccines for prevention of Ebola virus infection","volume":"17","author":"Ye","year":"2015","journal-title":"Microbes Infect."},{"key":"10.1016\/j.antiviral.2017.07.009_bib33","doi-asserted-by":"crossref","first-page":"25856","DOI":"10.1038\/srep25856","article-title":"Potent neutralizing monoclonal antibodies against Ebola virus infection","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2017.07.009_bib34","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2010.134","article-title":"An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector","volume":"5","author":"Zhou","year":"2010","journal-title":"Nat. Protoc."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T19:46:03Z","timestamp":1622490363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421730075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":34,"alternative-id":["S016635421730075X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.07.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}